Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Trial Using a Modified COG ABFM Regimen Backbone to Investigate Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)

NCT05681260 is registered in ClinicalTrials.gov with Children's Cancer Group, China as lead sponsor.

NCT NCT05681260
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05681260 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Trial Using a Modified COG ABFM Regimen Backbone to Investigate Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)
Lead sponsor
Children's Cancer Group, China
Phase
Phase 3
Overall status
Recruiting
Start date
February 6, 2023
Completion date
December 31, 2029
Enrollment
200 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

t-cell lymphoblastic lymphoma